Shield Therapeutics PLC
LSE:STX
Shield Therapeutics PLC
Shield Therapeutics Plc is a pharmaceutical company. The company is headquartered in Gateshead, Tyne And Wear and currently employs 16 full-time employees. The company went IPO on 2016-02-26. The firm specializes in the development and commercialization of late-stage pharmaceuticals which address areas of unmet medical need. The firm's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia. Ferric maltol is approved in the United States, European Union, United Kingdom and Switzerland for the treatment of iron deficiency with or without anemia in adults. Its pipeline product candidate, PT20, is an iron-based phosphate binder that has the potential to treat patients with hyperphosphatemia related to dialysis or non-dialysis dependent chronic kidney disease (CKD). PT20 has completed its Phase II pivotal study. Its subsidiaries include Shield Therapeutics (DE) GmbH, Shield TX (UK) Limited, Phosphate Therapeutics Limited, and others.
Shield Therapeutics Plc is a pharmaceutical company. The company is headquartered in Gateshead, Tyne And Wear and currently employs 16 full-time employees. The company went IPO on 2016-02-26. The firm specializes in the development and commercialization of late-stage pharmaceuticals which address areas of unmet medical need. The firm's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia. Ferric maltol is approved in the United States, European Union, United Kingdom and Switzerland for the treatment of iron deficiency with or without anemia in adults. Its pipeline product candidate, PT20, is an iron-based phosphate binder that has the potential to treat patients with hyperphosphatemia related to dialysis or non-dialysis dependent chronic kidney disease (CKD). PT20 has completed its Phase II pivotal study. Its subsidiaries include Shield Therapeutics (DE) GmbH, Shield TX (UK) Limited, Phosphate Therapeutics Limited, and others.
Record Net Revenue: Q2 ACCRUFeR net revenue doubled to $12.8 million from $6.4 million in Q1 2025.
Prescription Growth: 47,000 prescriptions in Q2, up 30% from Q1 and the company’s highest ever.
Rising Prices: Net selling price per prescription grew to $231 in Q2, up from $187 in Q1.
Cash Position: Quarter-end cash and equivalents rose to $10.8 million, aided by milestone payments.
Cash Flow Guidance: Management reiterated confidence in turning cash flow positive by end of 2025.
Digital & Field Success: Digital marketing now drives 300 of 800 new prescribers per month and is growing in importance alongside the sales force.
Sales Team Fully Staffed: The US field force is now at target levels (80 reps), after consolidating high-performing territories.
Consignment Channel Shrinking: Consignment-based prescriptions fell to 23% in Q2 from 27% in Q1, improving revenue mix.
Global Expansion: Progress made in Europe, Canada, Korea, China, and Japan, with new partnerships and milestone payments.
Peak Potential: ACCRUFeR’s estimated annual peak US revenue remains at $450 million, with low current market penetration.
